Heartflow, Inc. (HTFL) News
Track canonical SquawkNews coverage tagged to HTFL, Heartflow, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 7 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
HTFL: Plaque Analysis growth and new trials drive expansion toward an $11B TAM by 2030
AI-driven coronary artery disease diagnostics are accelerating growth, with Plaque Analysis adoption and revenue surging, supported by robust clinical data and expanding payer coverage. Strategic RCTs target a $6B asympt
EQUITY | Sep 09, 2026, 09:39 PM UTC
L
HTFL: Rapid Plaque Analysis growth and new trials target a doubling of addressable market by 2029
AI-driven coronary artery disease diagnostics are seeing rapid Plaque Analysis adoption, strong revenue growth, and expanding clinical evidence. New RCTs target a $6 billion asymptomatic market, aiming to double TAM by 2
EARNINGS | Sep 09, 2026, 09:04 PM UTC
L
Heartflow price target announced at $55.00 by UBS
UBS set a price target of $55.00 per share for Heartflow.
EQUITY | Sep 09, 2026, 01:33 PM UTC
H
HTFL - Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart
HTFL - Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half
GEOPOLITICS | Aug 28, 2026, 06:57 AM UTC
L
Heartflow to participate in Wells Fargo healthcare conference
Heartflow will participate in the Wells Fargo 21st Annual Healthcare Conference.
EQUITY | Aug 27, 2026, 08:08 PM UTC
L
HTFL - Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference
HTFL - Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference
EQUITY | Aug 27, 2026, 08:01 PM UTC
L
HeartFlow shares jump after strong Q2 adjusted EPS, raised outlook
HeartFlow Inc. (HTFL) posts better-than-expected second-quarter adjusted EPS and raises full-year 2026 revenue guidance to $246 million–$250 million from $228 million–$232 million.
EARNINGS | Aug 14, 2026, 07:47 PM UTC
L
Heartflow, Eton, Nu Holdings rise on earnings and guidance
Heartflow shares jump after quarterly adjusted EPS beats estimates while revenue misses; Eton Pharmaceuticals and Nu Holdings also climb after better-than-expected quarterly results, and Eton issues FY26 revenue guidance
EARNINGS | Aug 14, 2026, 01:55 PM UTC
L
HeartFlow raises full-year revenue and margin guidance after Q2 growth
HeartFlow reported Q2 2026 revenue of $64.1 million, up 48% year over year, and raised full-year revenue guidance to $246 million-$250 million while lifting non-GAAP gross margin guidance to about 82%.
EARNINGS | Aug 13, 2026, 09:49 PM UTC
L
HeartFlow raises FY2026 sales guidance to $246M–$250M
HeartFlow (NASDAQ: HTFL) raises FY2026 sales guidance to $246.000M–$250.000M from $218.000M–$222.000M versus a $230.073M estimate.
EARNINGS | Aug 13, 2026, 08:01 PM UTC
L
Heartflow reports Q2 2026 results and raises full-year 2026 guidance
Heartflow (HTFL) reports second-quarter 2026 financial results and raises its full-year 2026 guidance, according to TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:01 PM UTC
H
Cantor Initiates DUOT Overweight
Banks initiate coverage on several stocks
EQUITY | Jul 31, 2026, 11:38 AM UTC
L
Freedom Capital Markets Initiates Coverage On HeartFlow with Buy Rating, Announces Price Target of $37
Freedom Capital Markets analyst Gene Mannheimer initiates coverage on HeartFlow (NASDAQ: HTFL ) with a Buy rating and announces Price Target of $37.
EQUITY | Jul 01, 2026, 08:45 AM UTC